Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 15/20 | 0.59 |
| ▸ | RPS6KB1 | P23443 | 1/20 | 0.52 |
| ▸ | RAF1 | P04049 | 9/20 | 0.44 |
| ▸ | MAPK13 | O15264 | 2/20 | 0.43 |
| ▸ | RIPK2 | O43353 | 1/20 | 0.42 |
| ▸ | MAPK12 | P53778 | 1/20 | 0.42 |
| ▸ | MAPK11 | Q15759 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4372381 | 0.90 | MAPK14 (0.73) | MAPK14RPS6KB1RAF1MAPK13MAPK12 | |
| SCHEMBL4371790 | 0.89 | MAPK14 (0.53) | MAPK14RPS6KB1RAF1MAPK13RIPK2 | |
| SCHEMBL4368714 | 0.87 | MAPK14 (0.75) | MAPK14RPS6KB1MAPK13MAPK12MAPK11 | |
| SCHEMBL4370767 | 0.85 | MAPK14 (0.57) | MAPK14RPS6KB1RAF1MAPK13MAPK12 | |
| SCHEMBL4372572 | 0.85 | MAPK14 (0.56) | MAPK14RPS6KB1RAF1MAPK13 | |
| SCHEMBL4367329 | 0.79 | MAPK14 (0.63) | MAPK14RPS6KB1RAF1MAPK13RIPK2 | |
| SCHEMBL3548287 | 0.78 | MAPK14 (0.80) | MAPK14RPS6KB1MAPK13MAPK12MAPK11 | |
| SCHEMBL4367493 | 0.77 | MAPK14 (0.66) | MAPK14RPS6KB1RAF1MAPK13 | |
| SCHEMBL4367834 | 0.77 | RPS6KB1 (0.83) | MAPK14RPS6KB1MAPK13MAPK12MAPK11 | |
| SCHEMBL4370809 | 0.75 | MAPK14 (0.51) | MAPK14RPS6KB1RAF1MAPK13RIPK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1824843-A2 | INHIBITORS OF PROTEIN KINASES | Locus Pharmaceuticals, Inc. (US) | 2007-08-29 | — | — | EP | claimed |
| WO-2006062984-A2 | INHIBITORS OF PROTEIN KINASES | LOCUS PHARMACEUTICALS, INC. (US) | 2006-06-15 | — | — | WO | claimed |
| US-7612200-B2 | Inhibitors of protein kinases | LOCUS PHARMACEUTICALS, INC. (US) | 2009-11-03 | — | — | US | disclosed |
| US-7612200-B2 | Inhibitors of protein kinases | LOCUS PHARMACEUTICALS, INC. (US) | 2009-11-03 | — | — | US | disclosed |
| US-7612200-B2 | Inhibitors of protein kinases | LOCUS PHARMACEUTICALS, INC. (US) | 2009-11-03 | — | — | US | disclosed |
| US-20090192307-A1 | INHIBITORS OF PROTEIN KINASES | LOCUS PHARMACEUTICALS, INC. | 2009-07-30 | — | — | US | disclosed |
| US-20090192307-A1 | INHIBITORS OF PROTEIN KINASES | LOCUS PHARMACEUTICALS, INC. | 2009-07-30 | — | — | US | disclosed |
| US-20090192307-A1 | INHIBITORS OF PROTEIN KINASES | LOCUS PHARMACEUTICALS, INC. | 2009-07-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090192307-A1 | INHIBITORS OF PROTEIN KINASES | MAP3K20, MAP3K1, MAP3K19 | MAPK14 300/4885RPS6KB1 143/4885RAF1 37/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.